Acta Med. 2019, 62: 127-130

https://doi.org/10.14712/18059694.2019.129

Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer

David Bukaa, Josef Dvořákb, Igor Richterc, Pavel Škrobánekb, Tomáš Buchlerb, Bohuslav Melichard

aDepartment of Oncology and Radiotherapy, Charles University Medical School and Teaching Hospital, Hradec Králové, Czech Republic
bDepartment of Oncology, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic
cDepartment of Oncology, Regional Hospital, Liberec, Czech Republic
dDepartment of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic

Received March 13, 2019
Accepted June 24, 2019

References

1. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071–121. <https://doi.org/10.1152/physrev.00038.2010> <PubMed>
2. Cantelmo AR, Pircher A, Kalucka J, Carmeliet P. Vessel pruning or healing: endothelial metabolism as a novel target? Expert Opin Ther Targets 2013; 21: 239–47. <https://doi.org/10.1080/14728222.2017.1282465> <PubMed>
3. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73: 2943–48. <https://doi.org/10.1158/0008-5472.CAN-12-4354> <PubMed>
4. Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 2018; 9: 978. <https://doi.org/10.3389/fimmu.2018.00978> <PubMed>
5. Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013; 73: 539–49. <https://doi.org/10.1158/0008-5472.CAN-12-2325>
6. Wang Y, Yao X, Ge J, Hu F, Zhao Y. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. Scientific World Journal 2014; 2014: 102736.
7. Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 2015; 20: 660–73. <https://doi.org/10.1634/theoncologist.2014-0465> <PubMed>
8. Buka D, Dvorak J, Sitotova V, et al. The changes of tumor vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Cont Oncol (Pozn) 2017; 21: 48–53.
9. Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression. Mol Oncol 2017; 11: 805–23. <https://doi.org/10.1002/1878-0261.12095> <PubMed>
10. Laghi L, Bianchi P, Miranda E, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009; 10: 877–84. <https://doi.org/10.1016/S1470-2045(09)70186-X>
11. Kirilovsky A, Marliot F, El Sissy C, et al. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol 2016; 28: 373–82. <https://doi.org/10.1093/intimm/dxw021> <PubMed>
12. Becht E, Giraldo NA, Germain C, et al. Immune contexture, immunoscore, and malignanT cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol 2016; 130: 95–190. <https://doi.org/10.1016/bs.ai.2015.12.002>
13. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960–64. <https://doi.org/10.1126/science.1129139>
14. Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944–51. <https://doi.org/10.1200/JCO.2008.19.6147>
15. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610–18. <https://doi.org/10.1200/JCO.2010.30.5425>
16. Boland PM, Ma WW. Immunotherapy for colorectal cancer. Cancers (Basel) 2017; 9(5).pii: E50. <https://doi.org/10.3390/cancers9050050> <PubMed>
17. Tapia Rico G, Price TJ. Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. Expert Opin Biol Ther 2018; 18: 449–57. <https://doi.org/10.1080/14712598.2018.1444024>
18. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18: 1182–91. <https://doi.org/10.1016/S1470-2045(17)30422-9> <PubMed>
19. Clinicaltrials.gov, A service of the U.S. National Institutes of Health, http://clinicaltrials.gov.
20. Basile D, Garattini SK, Bonotto M, et al. Immunotherapy for colorectal cancer: where are we heading? Expert Opin Biol Ther 2017; 17: 709–21. <https://doi.org/10.1080/14712598.2017.1315405>
21. Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis 2017; 20: 185–204. <https://doi.org/10.1007/s10456-017-9552-y> <PubMed>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Archive